Study: NCT00608062

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GnRHant - Ganirelix acetate
Description: 1 subcutaneous injection at 0.5 mg then daily injections of 0.25 mg for 6 days (total of 7 days of injections); testing will occur on injection day 4 and day 7

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GnRHant - Ganirelix acetate
Description: 1 subcutaneous injection at 0.5 mg then daily injections of 0.25 mg for 6 days (total of 7 days of injections); testing will occur on injection day 4 and day 7

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GnRHant - Ganirelix acetate
Description: 1 subcutaneous injection at 0.5 mg then daily injections of 0.25 mg for 6 days (total of 7 days of injections); testing will occur on injection day 4 and day 7

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GnRHant - Ganirelix acetate
Description: 1 subcutaneous injection at 0.5 mg then daily injections of 0.25 mg for 6 days (total of 7 days of injections); testing will occur on injection day 4 and day 7

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GnRHant - Ganirelix acetate
Description: 1 subcutaneous injection at 0.5 mg then daily injections of 0.25 mg for 6 days (total of 7 days of injections); testing will occur on injection day 4 and day 7

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GnRHant - Ganirelix acetate
Description: 1 subcutaneous injection at 0.5 mg then daily injections of 0.25 mg for 6 days (total of 7 days of injections); testing will occur on injection day 4 and day 7

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GnRHant - Ganirelix acetate
Description: 1 subcutaneous injection at 0.5 mg then daily injections of 0.25 mg for 6 days (total of 7 days of injections); testing will occur on injection day 4 and day 7

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GnRHant - Ganirelix acetate
Description: 1 subcutaneous injection at 0.5 mg then daily injections of 0.25 mg for 6 days (total of 7 days of injections); testing will occur on injection day 4 and day 7

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Transdermal estradiol patch
Description: 0.075mg/d starting on day 4 of the injections following testing time point two; continue for 3 days and retest (day 7)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Transdermal estradiol patch
Description: 0.075mg/d starting on day 4 of the injections following testing time point two; continue for 3 days and retest (day 7)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Transdermal estradiol patch
Description: 0.075mg/d starting on day 4 of the injections following testing time point two; continue for 3 days and retest (day 7)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Transdermal estradiol patch
Description: 0.075mg/d starting on day 4 of the injections following testing time point two; continue for 3 days and retest (day 7)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Transdermal placebo patch
Description: Starting on day 4 of the injections following testing time point two; continue for 3 days and retest (day 7)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Transdermal placebo patch
Description: Starting on day 4 of the injections following testing time point two; continue for 3 days and retest (day 7)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Transdermal placebo patch
Description: Starting on day 4 of the injections following testing time point two; continue for 3 days and retest (day 7)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Transdermal placebo patch
Description: Starting on day 4 of the injections following testing time point two; continue for 3 days and retest (day 7)